CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
Uber Technologies maintains a $150 fair value with a 6.7% FCF yield and AV integration as buybacks continue. Read why UBER ...
When risk-reward shifts in my favour, I pay attention. These three shares stand out. The post 3 beaten down ASX shares I'd ...
Europe’s most fragile region is not sleepwalking toward war, but it is quietly recalibrating for it. Across the Western ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results